Lantern Pharma Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical crossroads, balancing cutting-edge computational biology against a fragile balance sheet. The core value proposition—using AI to rescue failed drugs—is scientifically compelling and supported by a growing portfolio of FDA designations. However, the financial data underscores the inherent volatility of the micro-cap biotech sector, where technical success is often decoupled from immediate solvency. The shift toward milestone-based vendor payments is a prudent attempt to manage burn, but it does not eliminate the fundamental need for significant capital to reach commercialization. Ultimately, the investment thesis hinges on whether the withZeta.ai platform can transition from a 'free service' to a revenue-generating product before the current cash runway expires in late 2026. If Lantern can secure enterprise AI partnerships or positive Phase 2 data for LP-300 or LP-184, it may trigger a massive re-rating. Conversely, the 'going concern' warning serves as a stark reminder that without a catalyst-driven liquidity event, the company remains highly vulnerable to the same binary risks that claimed the original developers of its rescued compounds.